Participants in Phase I trials are usually a small group of patients, often ranging between 20 to 80 individuals. These are typically patients with advanced cancer who have not responded to standard treatments. Participation is usually driven by the hope of finding a new effective therapy, even though the primary aim of these trials is not to assess efficacy but to determine safety and optimal dosing.
